Exscientia Business Update for Third Quarter 2021
Exscientia (Nasdaq: EXAI):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006300/en/
(Graphic: Business Wire)
Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the third quarter ended September 30, 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail on the business models underlying the Company’s pipeline of more than 25 programmes.
Highlights
Leveraging deep learning on patient tissue samples at scale to transform target discovery and patient selection
- Expanded investigation of patient tissue models in solid tumours, including ongoing analysis of EXS-617 in ovarian and breast cancer models
- Published EXALT-1 clinical trial results in Cancer Discovery that highlighted benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancer
- Completed acquisition of Allcyte, integrating leading tissue platform into Exscientia’s end-to-end drug discovery operations
Pipeline progress marked by candidate nomination, significant expansion of existing collaborations
- Partnered programmes
-
Expanded Bristol Myers Squibb collaboration to include potential targets across immunology and oncology; potential deal value beyond $1.3 billion
- BMS in-licensed first candidate from original 2019 collaboration, a potential first-in-class immunology medicine, triggering $20.0 million option exercise fee
- Co-owned programmes
- EXS-617: development candidate nominated for CDK7 inhibitor from expanded joint venture with GT Apeiron; additional translational data anticipated 1H 2022
- First two targets selected in EQRx joint venture
- Wholly and majority owned programmes
- EXS-21546: Phase 1 data for A2a antagonist in high adenosine signature cancers expected 1H 2022; translational research programmes for patient selection ongoing
- Entered into third collaboration with Bill & Melinda Gates Foundation that added portfolio of up to five antiviral small molecule drug candidates and accelerated development of SARS-CoV-2 lead programme
Strengthened balance sheet providing several years of cash runway to deliver AI-designed molecules and accelerate pipeline growth
- Expect between $75.0-$85.0 million in cash inflows from collaborations for full year 2021
- In October, closed $510.4 million gross aggregate financing, consisting of $350.4 million gross proceeds from upsized initial public offering and $160.0 million gross proceeds from concurrent private placement
- Cash at the end of the third quarter 2021, adjusted to include the net proceeds from the initial public offering completed on October 5, 2021, was $783.7 million
Expanding drug discovery and automation laboratories to scale capacity and operations
- Opened 21,000-square foot expansion of facilities at Oxford Science Park
- Building 26,000-square foot laboratory in Milton Park, Oxfordshire focused on the automation of chemistry and biology to accelerate drug discovery
- Building 50,000-square foot precision medicine centre of excellence in Vienna, Austria
- Added to U.S. footprint with expansion in Miami, opening of office in Boston, and key hires in strategic operations, technology and chemistry
“Exscientia is leading the modernisation of how new medicines are created by using AI in each step of discovery and development. Demonstrating our unique translational capabilities, we recently published groundbreaking results showing our AI precision medicine platform can improve outcomes for cancer patients. We have also propelled our pipeline through substantial investment in our own new medicine programmes, significantly expanded our relationship with Bristol Myers Squibb, and added a portfolio of pandemic preparedness antivirals to our work with the Bill and Melinda Gates Foundation. Finally, we began expanding our labs, investing in scaling our precision medicine platform and automated synthesis and screening,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “We have incredible momentum, and with our solid balance sheet post IPO, we will continue investing in innovation that can enable the rapid translation of today’s most promising science into tomorrow’s best possible medicines.”
Investor Call and Webcast Information
Exscientia will host a conference call on November 18 at 1:30 p.m. GMT / 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 760 294 1674 (U.S.), +44 203 059 5869 (U.K.), +44 203 059 8128 (International) and mentioning Exscientia. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.
Third Quarter Financial Results
For the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of £1.000 to $1.347, which was the noon buying rate of the Federal Reserve Bank of New York on September 30, 2021.
Revenue: Revenue for the nine months ended September 30, 2021, was $31.3 million, an increase of $23.6 million compared to the nine months ended September 30, 2020, primarily due to the achievement of the opt-in milestone on the first candidate in-licensed on Exscientia’s collaboration with BMS.
R&D and cost of drug discovery: Due to various collaboration structures, R&D expenses may be included under multiple accounting line items. The tables below show how these expenses are separated across the accounting categories.
Three months ended September 30, 2021 ($ millions):
|
COGS |
R&D |
Share of JV loss |
Total |
Partnered Programmes |
6.5 |
–– |
–– |
6.5 |
Co-owned Programmes |
–– |
1.0 |
0.3 |
1.4 |
Internal Pipeline and Technology Development |
–– |
16.4 |
–– |
16.4 |
Total |
6.5 |
17.4 |
0.3 |
24.2 |
Nine months ended September 30, 2021 ($ millions):
|
COGS |
R&D |
Share of JV loss |
Total |
Partnered Programmes |
16.6 |
–– |
–– |
16.6 |
Co-owned Programmes |
–– |
1.8 |
1.3 |
3.1 |
Internal Pipeline and Technology Development |
–– |
32.3 |
–– |
32.3 |
Total |
16.6 |
34.1 |
1.3 |
52.0 |
General and administrative expenses: G&A expenses for the nine months ended September 30, 2021 were $26.1 million, or 34% of total operating expenses. For the nine months ended September 30, 2021, G&A expenses grew by $20.2 million compared to the nine months ended September 30, 2020, primarily associated with both an expansion of internal capabilities as well as transaction-related professional services.
Financial Outlook for 2021 & 2022
For the first three quarters of 2021, Exscientia announced three new partnerships and received $65.4 million cash inflows from its collaborations. The Company expects to receive a total of $75.0-$85.0 million by year-end 2021, and anticipates 2022 cash inflows from collaborations will exceed 2021 cash inflows from collaborations. Exscientia expects to end 2021 with cash and cash equivalents between $745.0-$755.0 million.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in £
millions, except per share data)
|
Three months ended September 30, |
Nine months ended September 30, |
||
|
2021 |
2020 |
2021 |
2020 |
Revenue |
17.6 |
1.0 |
23.2 |
5.7 |
Cost of sales |
(4.8) |
(3.3) |
(12.3) |
(10.3) |
Research and development expenses |
(12.9) |
(2.9) |
(25.3) |
(7.2) |
General and administrative expenses |
(8.6) |
(1.5) |
(19.4) |
(4.4) |
Operating expenses |
(26.3) |
(7.7) |
(57.0) |
(21.8) |
Foreign exchange gains/(losses) |
1.7 |
(2.4) |
(1.2) |
(0.9) |
Other income |
1.8 |
0.4 |
3.0 |
0.8 |
Operating loss |
(5.3) |
(8.7) |
(32.0) |
(16.2) |
Finance income/(expense) |
(0.1) |
(0.0) |
(0.1) |
0.0 |
Share of loss on joint ventures |
(0.2) |
(0.4) |
(1.0) |
(0.9) |
Loss on derivative financial instruments |
(1.4) |
–– |
–– |
–– |
Loss before taxation |
(6.9) |
(9.2) |
(33.1) |
(17.0) |
Income tax benefit |
1.9 |
0.8 |
4.0 |
1.5 |
Loss for the period |
(5.1) |
(8.4) |
(29.1) |
(15.6) |
Net loss per share |
(0.06) |
(0.08) |
(0.32) |
(0.15) |
CONSTANT CURRENCY CONVERSION (unaudited)
(in $ millions, except per share data, at the rate of £1.000 to $1.347)
|
Three months ended September 30, |
Nine months ended September 30, |
||
|
2021 |
2020 |
2021 |
2020 |
Revenue |
23.8 |
1.3 |
31.3 |
7.7 |
Cost of sales |
(6.5) |
(4.5) |
(16.6) |
(13.8) |
Research and development expenses |
(17.4) |
(3.8) |
(34.1) |
(9.7) |
General and administrative expenses |
(11.6) |
(2.0) |
(26.1) |
(6.0) |
Operating expenses |
(35.5) |
(10.4) |
(76.8) |
(29.4) |
Foreign exchange gains/(losses) |
2.2 |
(3.2) |
(1.7) |
(1.2) |
Other income |
2.4 |
0.5 |
4.0 |
1.1 |
Operating loss |
(7.1) |
(11.7) |
(43.1) |
(21.8) |
Finance income/(expense) |
(0.1) |
(0.0) |
(0.2) |
0.0 |
Share of loss on joint ventures |
(0.3) |
(0.6) |
(1.3) |
(1.2) |
Loss on derivative financial instruments |
(1.8) |
–– |
–– |
–– |
Loss before taxation |
(9.3) |
(12.3) |
(44.6) |
(22.9) |
Income tax benefit |
2.5 |
1.1 |
5.3 |
2.0 |
Loss for the period |
(6.8) |
(11.3) |
(39.3) |
(21.0) |
Net loss per share |
(0.08) |
(0.11) |
(0.43) |
(0.20) |
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.
Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on the Company’s business, and including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission (SEC) on September 10, 2021, as amended (File No. 333-259431), and other filings that Exscientia makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006300/en/
Contact information
Investors:
Sara Sherman
investors@exscientia.ai
Media:
Amanda Galgay
media@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Welcomes Global Technology Leaders as Licensees and Licensors to New Video Distribution Patent Pool2.7.2025 03:00:00 EEST | Press release
Access Advance LLC ("Advance") today announced the inaugural roster of licensees and licensors for its Video Distribution Patent ("VDP") Pool, marking a significant milestone in the program's rapid market adoption since its January announcement. The participation of major global companies heavily involved in video codec technology demonstrates strong industry support for the comprehensive licensing solution covering HEVC, VVC, VP9, and AV1 codecs. The VDP Pool has successfully attracted a group of licensees/licensors including ByteDance, Kuaishou, NTT Docomo, and Tencent. This represents the beginning of what Access Advance expects to be widespread adoption among content streaming providers seeking simplified codec licensing. The licensees’ participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. "We're pleased to welcome ByteDance, Kuaishou, NTT Docomo and Tencent as our
Intralot S.A. to Acquire Bally’s International Interactive Business in a Transaction that Creates a Global Gaming Technology and Services Company in Lottery and Digital Online Gaming Markets1.7.2025 22:10:00 EEST | Press release
Intralot S.A. (ATSE: INLOT) (“Intralot”) and Bally’s Corporation (NYSE: BALY) (“Bally’s”) today announced that their respective Boards of Directors approved their entry into a definitive transaction agreement (“Transaction Agreement”) pursuant to which Intralot will acquire Bally’s International Interactive business (the “International Interactive Business”) in a cash-and-shares transaction that values the International Interactive Business at an enterprise value of €2.7 billion (the “Transaction”). The consideration for the acquisition of the International Interactive Business will comprise a combination of cash paid by Intralot and newly issued shares delivered by Intralot to Bally’s, as more specifically detailed below. As part of the Transaction, Intralot expects to refinance part of its existing debt facilities and Bally’s also expects to repay secured debt from the cash proceeds. The Transaction consideration to Bally’s, after assumptions of certain liabilities by the involved pa
Valeo Foods Group Acquires Melegatti Cakes Expanding the Italian Bakery Portfolio1.7.2025 19:21:00 EEST | Press release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the assets of an Italian panettone, pandoro and croissant producer, Melegatti 1894 S.p.A.This acquisition is another step forward in Valeo Foods Groups’ strategy to expand its baked sweet treats portfolio, and reinforces Valeo’s commitment to bringing authentic Italian confections and established regional brands to a wider international audience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702677156/en/ Melegatti Founded in 1894 in Verona, Melegatti has a strong reputation for artisanal cakes - particularly pandoro, panettone and filled croissants - traditional recipes, and a rich Italian heritage, Melegatti has a proud legacy founded on family values, craftsmanship, and a passion for quality. “We are excited to welcome Melegatti into the Valeo Foods Group,” said Ronald Kers, Group CEO. “This acquisition
PUMA and Borussia Dortmund Extend Partnership1.7.2025 19:18:00 EEST | Press release
Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701775493/en/ Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. Since the start of their partnership in the 2012/13 season, BVB has celebrated many successes, such as reaching the finals of the 2012/13 and 2023/24 UEFA Champions League and winning the 2016/17 and 2020/21 German DFB Cup. The club is currently participating in the FIFA Club World Cup, where it has already reached the round of 16. BVB continues to set the standard in European football w
Gogo Galileo HDX Coming to Cessna Citation Jet Models1.7.2025 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. The global Low Earth Orbit (LEO) solution allows customers to enjoy one of the best possible in-flight connectivity and aviation experiences, no matter where their journey takes them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701750049/en/ Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. (Photo: Textron Aviation) By offering Gogo Galileo HDX as an aftermarket upgrade, the Textron Aviation support team is ensuring customers benefit from a g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom